4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc.（FDMT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · FDMT · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
11
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
4D Molecular Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
FDMT 季度内部人买卖趋势
FDMT 内幕交易卖出 · FDMT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · FDMT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
FDMT 高管卖出股份 · FDMT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Kirn David See Remarks · Director | Sale | 1,922 | $19K | Form 4 |
| Mar 20, 2026 | Gupta Ashoo VP, Finance and Controller | Option | 865 | — | Form 4 |
| Mar 20, 2026 | Gupta Ashoo VP, Finance and Controller | Option | 221 | — | Form 4 |
| Mar 20, 2026 | Gupta Ashoo VP, Finance and Controller | Sale | 80 | $689 | Form 4 |
| Mar 20, 2026 | Gupta Ashoo VP, Finance and Controller | Sale | 310 | $3K | Form 4 |
| Dec 20, 2025 | Gupta Ashoo VP, Finance and Controller | Option | 866 | — | Form 4 |
| Dec 20, 2025 | Gupta Ashoo VP, Finance and Controller | Option | 220 | — | Form 4 |
| Dec 20, 2025 | Gupta Ashoo VP, Finance and Controller | Sale | 79 | $686 | Form 4 |
| Dec 20, 2025 | Gupta Ashoo VP, Finance and Controller | Sale | 310 | $3K | Form 4 |
| Dec 16, 2025 | Bizily Scott Chief Legal Officer | Option | 1,635 | $7K | Form 4 |
| Dec 16, 2025 | Bizily Scott Chief Legal Officer | Sale | 1,635 | $18K | Form 4 |
| Dec 12, 2025 | THEUER CHARLES Director | Option | 9,333 | $11K | Form 4 |
| Nov 17, 2025 | Bizily Scott Chief Legal Officer | Option | 1,635 | $7K | Form 4 |
| Nov 17, 2025 | Bizily Scott Chief Legal Officer | Sale | 1,635 | $17K | Form 4 |
| Oct 24, 2025 | Bizily Scott Chief Legal Officer | Option | 1,084 | $7K | Form 4 |
| Oct 24, 2025 | Bizily Scott Chief Legal Officer | Sale | 2,678 | $32K | Form 4 |
| Oct 16, 2025 | Bizily Scott Chief Legal Officer | Option | 1,635 | $7K | Form 4 |
| Oct 16, 2025 | Bizily Scott Chief Legal Officer | Sale | 1,635 | $17K | Form 4 |
| Oct 9, 2025 | Bizily Scott Chief Legal Officer | Sale | 2,408 | $24K | Form 4 |
| Sep 23, 2025 | Bizily Scott Chief Legal Officer | Sale | 2,407 | $19K | Form 4 |
| Dec 9, 2024 | RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Other | 535,000 | — | Form 4 |
| Sep 16, 2024 | Bizily Scott Chief Legal Officer | Option | 500 | $3K | Form 4 |
| Sep 16, 2024 | Bizily Scott Chief Legal Officer | Sale | 500 | $8K | Form 4 |
| Aug 19, 2024 | Bizily Scott Chief Legal Officer | Option | 500 | $3K | Form 4 |
| Aug 19, 2024 | Bizily Scott Chief Legal Officer | Sale | 500 | $8K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 FDMT 内幕交易
FDMT 内幕交易
4D Molecular Therapeutics, Inc.（FDMT）内幕交易数据来源于公司内部人（包括Bizily Scott (Chief Legal Officer), Gupta Ashoo (VP, Finance and Controller), Kirn David (See Remarks · Director)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。FDMT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看4D Molecular Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
FDMT 内幕交易 · 5个问题4D Molecular Therapeutics, Inc.（FDMT）的内部人包括高管和董事，如Bizily Scott (Chief Legal Officer), Gupta Ashoo (VP, Finance and Controller), Kirn David (See Remarks · Director)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026